Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy

Medientyp: E-Artikel

Titel: Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy

Beteiligte: Obradovic, Danilo Momira [VerfasserIn]; Büttner, Petra [VerfasserIn]; Rommel, Karl-Philipp [VerfasserIn]; Blazek, Stephan [VerfasserIn]; Loncar, Goran [VerfasserIn]; von Haehling, Stephan [VerfasserIn]; von Roeder, Maximilian [VerfasserIn]; Lücke, Christian [VerfasserIn]; Gutberlet, Matthias [VerfasserIn]; Thiele, Holger [VerfasserIn]; Lurz, Philipp [VerfasserIn]; Besler, Christian [VerfasserIn]

Erschienen: Basel : MDPI, [2023]

Sprache: Englisch

Schlagwörter: science-biology ; inflammatory cardiomyopathy; endomyocardial biopsy; dilated cardiomyopathy; ELISA; sST2 ; Biologie

Entstehung:

Anmerkungen: Hinweis: Link zur Erstveröffentlichung URL: https://doi.org/10.3390/cells11030414

Beschreibung: Introduction: Inflammatory cardiomyopathy (ICM) frequently leads to myocardial fibrosis, resulting in permanent deterioration of the left ventricular function and an unfavorable outcome. Soluble suppression of tumorigenicity 2 receptor (sST2) is a novel marker of inflammation and fibrosis in cardiovascular tissues. sST2 was found to be helpful in predicting adverse outcomes in heart failure patients with reduced ejection fraction. The aim of this study was to determine the association of sST2 plasma levels with cardiac magnetic resonance (CMR) and echocardiography imaging features of left ventricular impairment in ICM patients, as well as to evaluate the applicability of sST2 as a prognosticator of the clinical status in patients suffering from ICM. Methods: We used plasma samples of 89 patients presenting to the Heart Center Leipzig with clinically suspected myocardial inflammation. According to immunohistochemical findings in endomyocardial biopsies (EMB) conducted in the context of patients’ diagnostic work-up, inflammatory cardiomyopathy was diagnosed in 60 patients (ICM group), and dilated cardiomyopathy in 29 patients (DCM group). All patients underwent cardiac catheterization for exclusion of coronary artery disease and CMR imaging on 1.5 or 3 Tesla. sST2 plasma concentration was determined using ELISA. Results: Mean plasma concentration of sST2 in the whole patient cohort was 45.8 ± 26.4 ng/mL (IQR 27.5 ng/mL). In both study groups, patients within the highest quartile of sST2 plasma concentration had a significantly lower left ventricular ejection fraction (LV-EF) compared to patients within the lowest sST2 plasma concentration quartile (26 ± 11% vs. 40 ± 13%, p = 0.05 for ICM and 24 ± 13% vs. 51 ± 10%, p = 0.004 for DCM). sST2 predicted New York Heart Association (NYHA) class III/IV at 12 months follow-up more efficiently in ICM compared to DCM patients (AUC 0.85 vs. 0.61, p = 0.02) and was in these terms superior to NT-proBNP and cardiac troponin T. ICM patients with sST2 plasma concentration higher than 44 ng/mL at baseline had a significantly higher probability of being assigned to NYHA class III/IV at 12 months follow-up (hazard ratio 2.8, 95% confidence interval 1.01–7.6, log rank p = 0.05). Conclusion: Plasma sST2 levels in ICM patients reflect the degree of LV functional impairment at hospital admission and predict functional NYHA class at mid-term follow-up. Hence, ST2 may be helpful in the evaluation of disease severity and in the prediction of the clinical status in ICM patients.

Zugangsstatus: Freier Zugang

Rechte-/Nutzungshinweise: Namensnennung (CC BY)

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: